ValuEngine downgraded shares of Charles River Laboratories Intl. (NYSE:CRL) from a buy rating to a hold rating in a report published on Tuesday.

Several other equities analysts have also recently commented on the stock. KeyCorp raised shares of Charles River Laboratories Intl. from a sector weight rating to an overweight rating and raised their price target for the company from $115.85 to $130.00 in a research report on Friday, June 15th. Jefferies Financial Group reissued a buy rating and issued a $140.00 price target on shares of Charles River Laboratories Intl. in a research report on Friday, July 20th. Royal Bank of Canada raised shares of Charles River Laboratories Intl. from a sector perform rating to an outperform rating and set a $131.00 price objective for the company in a research report on Tuesday, July 17th. TheStreet raised shares of Charles River Laboratories Intl. from a c+ rating to a b+ rating in a research report on Thursday, May 10th. Finally, SunTrust Banks lifted their price objective on shares of Charles River Laboratories Intl. to $135.00 and gave the stock a buy rating in a research report on Thursday, August 9th. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $125.40.

Shares of CRL stock opened at $121.77 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.72 and a quick ratio of 1.48. Charles River Laboratories Intl. has a 52 week low of $96.70 and a 52 week high of $130.66. The company has a market capitalization of $5.84 billion, a price-to-earnings ratio of 21.32, a price-to-earnings-growth ratio of 1.52 and a beta of 0.66.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $570.65 million. During the same quarter last year, the company posted $1.29 EPS. The firm’s revenue was up 24.8% compared to the same quarter last year. equities analysts forecast that Charles River Laboratories Intl. will post 5.91 EPS for the current fiscal year.

In other news, COO Davide Molho sold 11,600 shares of Charles River Laboratories Intl. stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $125.00, for a total transaction of $1,450,000.00. Following the completion of the sale, the chief operating officer now directly owns 22,079 shares of the company’s stock, valued at approximately $2,759,875. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Birgit Girshick sold 3,978 shares of Charles River Laboratories Intl. stock in a transaction on Tuesday, July 17th. The stock was sold at an average price of $119.90, for a total transaction of $476,962.20. Following the sale, the insider now directly owns 18,999 shares of the company’s stock, valued at $2,277,980.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,258 shares of company stock valued at $4,001,244. Corporate insiders own 2.10% of the company’s stock.

A number of large investors have recently made changes to their positions in CRL. Signaturefd LLC acquired a new stake in Charles River Laboratories Intl. during the 1st quarter worth $105,000. NumerixS Investment Technologies Inc acquired a new stake in Charles River Laboratories Intl. during the 2nd quarter worth $122,000. Adviser Investments LLC acquired a new stake in Charles River Laboratories Intl. during the 1st quarter worth $152,000. Wsfs Capital Management LLC acquired a new stake in Charles River Laboratories Intl. during the 2nd quarter worth $203,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Charles River Laboratories Intl. during the 2nd quarter worth $212,000. Hedge funds and other institutional investors own 97.76% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Technical Analysis of Stocks, How Can It Help

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.